Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that is among the most selective growth hormone secretagogues ever created. It behaves as a ghrelin mimetic, by binding to the specific GHRH receptor (GHS-R1a) on pituitary somatotrophs to trigger pulsatile GH secretion without markedly raising cortisol, ACTH, prolactin, and other stress hormones, unlike non-selective GHRPs like GHRP-6 or hexarelin.
Ipamorelin is a potent dose-dependent GH secretagogue that not only stimulates robust production of GH in vivo and in vitro, but it has been shown to hasten gastric emptying in models of postoperative ileus, alter body composition parameters, and support recovery processes, including modulation of gastrointestinal and metabolic parameters 4-7. Short-term behavioral or biochemical assays. The 5 mg vial format will allow you to perform acute dose response curves, pilot protocols, and the aforementioned short-term behavioral or biochemical assays. It is not approved by the FDA for any therapeutic use, and so is solely an investigational research compound.
Disclaimer: Ipamorelin is not FDA-approved for human use and is still available only through research studies.
Ready to Begin Your Research with Ipamorelin? Order Now!
How does Ipamorelin work? What are The Research Studies Describing
Ipamorelin is a selective agonist for the growth hormone secretagogue receptor 1a subtype (GHS-R1a) located in the pituitary gland and hypothalamus. This initiates a signaling cascade that elevates intracellular calcium and cAMP, resulting in stimulation of GH exocytosis from somatotroph cells in a pulsatile and physiological manner.
Unlike non-selective secretagogues, Ipamorelin has little to no effect on the hypothalamic-pituitary-adrenal axis or ACTH/cortisol release. In rat pituitary cell cultures, SIHY-030 yielded an EC₅₀ of ~1.3 nmol/L for GH release, comparable to GHRP-6 but with greater specificity.
When administered intravenously in vivo, Ipamorelin evokes a dose-dependent GH release with an estimated ED₅₀ of 80 nmol/kg in anesthetized rats and 2 nmol/kg in conscious swine without increasing prolactin, TSH, LH, FSH, or cortisol.
In models of postoperative ileus (POI), Ipamorelin improves gastric emptying by ~52% versus controls, with mechanisms including the cholinergic excitatory pathway as well as stimulating smooth muscle contractility via GHS-R receptors.
These properties make Ipamorelin an ideal drug to investigate selective GH pulsatility, gastrointestinal motility, and neuroendocrine reward circuits in controlled laboratory settings.
Ipamorelin Benefits (Backed by Research)
Ipamorelin has been studied in other preclinical research settings. Key observations from studies include:
1. GHR (Growth Hormone Releasing) Agonists
Ipamorelin produces potent, dose-dependent GH secretion from pituitary cells and in whole animals with minimal off-target hormonal effects shown in vitro and in vivo models. Unlike the non-selective agents, it better preserves natural pulsatile GH patterns.
2. Accelerates Gastric Motility and Emptying of the Stomach in POI Models
Ipamorelin has been demonstrated to reverse the inhibitory effects of surgery on gastric contractility and accelerate gastric emptying in rodent postoperative ileus studies, through GHS-R-mediated cholinergic pathways, including increased acetylcholine release.
3. Affect Body Composition and Metabolic Markers
Ipamorelin appears to benefit adiposity and lean mass, in addition to metabolic signaling, as shown in animal models of aging or hormonal imbalance. This occurs likely through both a sustained elevation in gH as well as improved signaling pathways enhancing protein synthesis.
4. Provides Recovery in Models of Gastrointestinal Dysmotility
We conclude that ipamorelin restores EFS responses and increases smooth muscle contractility in isolated gastric fundus preparations from surgically stressed animals, indicating a potential utility for investigating mechanisms of postoperative recovery.
5. Maintains High Selectivity and Tolerability Profile
Unlike GHRP-6, Ipamorelin has a very slight pharmacological elevation of cortisol, ACTH or prolactin and therefore is suitable for laboratory research studies wherein clean GH stimulation is desired without activation of the stress axis.
Note: All these benefits are based on research studies or animal models. Ipamorelin is not FDA-approved for human consumption.
Dosage Information for Ipamorelin 5 mg: In Research Environment
Ipamorelin is most commonly available in lyophilized powder as a lab sample (5 mg vials) of which is reconstituted for use. So, low microgram doses are used in studies to preferentially activate certain GHS-R1a pathways and avoid non-specific actions.
1. Standard Quantitative Range
- Effective doses in rodent models: 50–200 μg/kg (subcutaneous or intravenous)
- 80–150/kg per administration – Common research range
- Goals: Effective GH pulses and motility effects, prevent desensitization
2. Initial Calibration (Baseline Phase)
- First dose: Lower end (i.e., 50–100 μg/kg)
- Frequency t: A single acute exposure after low-dose chronic exposure
- Rationale: Dose-response curve of GH secretion or motility endpoints and acute receptor activation
3. Maintenance and Longitudinal Observation
- Target: 100–180 μg/kg per day or every other day
- Treatment schedule: 5–14 days in chronic models, acute or repeated dosing for behavioral/motility studies
- Rationale: Continue GHS-R signaling and examine the cumulative effects of altered GH dynamics, gastric emptying, and metabolic markers
How to effectively compound Ipamorelin 5 mg for your research application.
This method ensures that the stability of the peptide remains intact as one properly reconstitutes it.
Supplies Needed Before Mixing
- Peptide Ipamorelin, 5mg vial
- Bacteriostatic water
- Alcohol swabs
- Insulin syringe
- Clean and sanitized surface
Step-by-Step Reconstitution Process
1. Clean the tops of vials with alcohol swabs.
2. Vial solution reconstitution Step 1: Draw the desired volume of bacteriostatic water into the syringe (generally only 1-2 mL for a 5 mg vial).
3. Add water slowly along the wall of the vial to avoid foaming.
4. Gently swirl (do not shake) until dissolved, and the solution is clear.
5. Store the vial that has been reconstituted at 2–8°C and protect from light.
When to Expect Results From Ipamorelin
Research timelines differ by model, route, dose, and endpoint. In a good sense, effects come very quickly because of direct GHS-R1a agonism.
Phase 1: Initial Response (1-7 Days)
- Induction of a pulse of acute GH and high plasma GH levels
- Apparent increase in mucosa contractility and motility markers
- Early alterations in dopamine release and reward-circuit activation
Phase 2: Building up a Structure — 1–3 Weeks
- In this model, a sustained selective GH secretion with repeated dosing
- Restoration of gastric emptying and multi-smooth muscle responses in motility models
- Multi-level modulation of metabolic and neuroendocrine signaling
Phase 3: Maturation and Optimization (4–8 Weeks)
- Chronic studies of GH pulsatility & body composition effects
- Reestablishment of motility and contractility in postoperative models
- Motivational and reward pathways mediated by maximal GHS-R activation
Phase 4: Longitudinal Maintenance and Stability
- Ongoing pathway support with stable dosing
- In some models, the prevention of regression upon withdrawal
- Alteration of GH dynamics and GI function in the long-run
Referenced Studies
1. https://pubmed.ncbi.nlm.nih.gov/9849822/
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4863553/
3. https://clinicaltrials.gov/study/NCT01280344